Nippon Shinyaku Collaborates with Atsena Therapeutics to Commercialize ATSN-101 Across the US and Japan
Shots:
- Nippon Shinyaku has signed an exclusive licensing agreement with Atsena to commercialize ATSN-101 in the US as well as for developing & commercializing it across Japan to treat Leber congenital amaurosis due to biallelic mutations in GUCY2D (LCA1)
- Nippon Shinyaku gains exclusive commercial rights of ATSN-101 in the US (by NS Pharma) & Japan, while Atsena retains global rights plus will receive upfront, milestones, sales-based downstream royalties & development cost reimbursements, incl. for planned pivotal trial
- ATSN-101 is a subretinal AAV5 gene therapy for LCA1 being investigated under P-I/II study. The 12mos. treatment showed durable vision improvements & good tolerance at high doses, with results published in The Lancet
Ref: Atsena Therapeutics | Image: Atsena Therapeutics & Nippon Shinyaku
Related News:- Atsena Therapeutics’ ATSN-201 Gains the US FDA’s Rare Pediatric Disease Designation for Treating Retinoschisis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
